Ryvu Therapeutics (RVU) investor relations material

Strategic focus and pipeline highlights

• Advancing first-in-class oncology therapeutics, with romaciclib (CDK8/19 inhibitor) as the lead asset showing efficacy in post-venetoclax AML and myelofibrosis, and expansion into medulloblastoma and other solid tumors.

• Broad pipeline includes RVU305 (PRMT5 inhibitor) for MTAP-deleted cancers, novel ADC payloads, and precision oncology targets via the ONCO Prime platform.

• End-to-end R&D capabilities in a state-of-the-art Krakow facility, with global clinical reach and collaborations with BioNTech, Exelixis, and Menarini.

Clinical development and data

• Romaciclib demonstrated clinical activity in relapsed/refractory AML post-venetoclax, with a 43% CR/CRi rate in a dose optimization cohort and favorable safety profile.

• In myelofibrosis, romaciclib showed durable symptom improvement and spleen volume reduction, especially in patients with ASXL1/CALR mutations.

• RVU305 exhibited best-in-class preclinical efficacy and brain penetration in MTAP-deleted tumor models, with IND-enabling studies completed.

Market opportunity and financials

• High unmet need in AML and MF, with potential to set new standards of care post-venetoclax and post-JAK inhibitor failure; global AML market projected to reach $6.6B by 2031.

• Q1 2026 revenues at €5.1M, with €17.6M cash and €20.6M in secured grants as of May 2026; strong financial position supported by partnerships and non-dilutive funding.